Gilead Sciences (GILD) will acquire its partner Arcellx (ACLX) in a deal valued at up to $7.8 billion, marking its largest acquisition since 2020. The move aims to expand Gilead’s cancer treatment portfolio beyond its core HIV and liver disease drugs.
23 Feb 2026-17:58
23 Feb 2026-17:58
